Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections

Iuliia Gilchuk; Pavlo Gilchuk; Gopal Sapparapu; Rebecca Lampley; Vidisha Singh; Nurgun Kose; David L. Blum; Laura J. Hughes; Panayampalli S. Satheshkumar; Michael B. Townsend; Ashley V. Kondas; Zachary Reed; Zachary Weiner; Victoria A. Olson; Erika Hammarlund; Hans Peter Raue; Mark K. Slifka; James C. Slaughter; Barney S. Graham; Kathryn M. Edwards; Roselyn J. Eisenberg; Gary H. Cohen; Sebastian Joyce; James E. Crowe

doi:10.1016/j.cell.2016.09.049

Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections

Iuliia Gilchuk, Pavlo Gilchuk, Gopal Sapparapu, Rebecca Lampley, Vidisha Singh, Nurgun Kose, David L. Blum, Laura J. Hughes, Panayampalli S. Satheshkumar, Michael B. Townsend, Ashley V. Kondas, Zachary Reed, Zachary Weiner, Victoria A. Olson, Erika Hammarlund, Hans Peter Raue, Mark K. Slifka, James C. Slaughter, Barney S. Graham, Kathryn M. EdwardsRoselyn J. Eisenberg, Gary H. Cohen, Sebastian Joyce, James E. Crowe

Research output: Contribution to journal › Article

19 Scopus citations

Abstract

Monkeypox (MPXV) and cowpox (CPXV) are emerging agents that cause severe human infections on an intermittent basis, and variola virus (VARV) has potential for use as an agent of bioterror. Vaccinia immune globulin (VIG) has been used therapeutically to treat severe orthopoxvirus infections but is in short supply. We generated a large panel of orthopoxvirus-specific human monoclonal antibodies (Abs) from immune subjects to investigate the molecular basis of broadly neutralizing antibody responses for diverse orthopoxviruses. Detailed analysis revealed the principal neutralizing antibody specificities that are cross-reactive for VACV, CPXV, MPXV, and VARV and that are determinants of protection in murine challenge models. Optimal protection following respiratory or systemic infection required a mixture of Abs that targeted several membrane proteins, including proteins on enveloped and mature virion forms of virus. This work reveals orthopoxvirus targets for human Abs that mediate cross-protective immunity and identifies new candidate Ab therapeutic mixtures to replace VIG.

Original language	English (US)
Pages (from-to)	684-694.e9
Journal	Cell
Volume	167
Issue number	3
DOIs	https://doi.org/10.1016/j.cell.2016.09.049
State	Published - Oct 20 2016

Keywords

antigen specificity
cross-neutralization
human monoclonal antibodies
poxvirus infections
protective immunity
smallpox vaccine

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1016/j.cell.2016.09.049

Fingerprint Dive into the research topics of 'Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections'. Together they form a unique fingerprint.

Cite this

Gilchuk, I., Gilchuk, P., Sapparapu, G., Lampley, R., Singh, V., Kose, N., Blum, D. L., Hughes, L. J., Satheshkumar, P. S., Townsend, M. B., Kondas, A. V., Reed, Z., Weiner, Z., Olson, V. A., Hammarlund, E., Raue, H. P., Slifka, M. K., Slaughter, J. C., Graham, B. S., ... Crowe, J. E. (2016). Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections. Cell, 167(3), 684-694.e9. https://doi.org/10.1016/j.cell.2016.09.049

Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections. / Gilchuk, Iuliia; Gilchuk, Pavlo; Sapparapu, Gopal; Lampley, Rebecca; Singh, Vidisha; Kose, Nurgun; Blum, David L.; Hughes, Laura J.; Satheshkumar, Panayampalli S.; Townsend, Michael B.; Kondas, Ashley V.; Reed, Zachary; Weiner, Zachary; Olson, Victoria A.; Hammarlund, Erika; Raue, Hans Peter; Slifka, Mark K.; Slaughter, James C.; Graham, Barney S.; Edwards, Kathryn M.; Eisenberg, Roselyn J.; Cohen, Gary H.; Joyce, Sebastian; Crowe, James E.

In: Cell, Vol. 167, No. 3, 20.10.2016, p. 684-694.e9.

Research output: Contribution to journal › Article

Gilchuk, I, Gilchuk, P, Sapparapu, G, Lampley, R, Singh, V, Kose, N, Blum, DL, Hughes, LJ, Satheshkumar, PS, Townsend, MB, Kondas, AV, Reed, Z, Weiner, Z, Olson, VA, Hammarlund, E, Raue, HP, Slifka, MK, Slaughter, JC, Graham, BS, Edwards, KM, Eisenberg, RJ, Cohen, GH, Joyce, S & Crowe, JE 2016, 'Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections', Cell, vol. 167, no. 3, pp. 684-694.e9. https://doi.org/10.1016/j.cell.2016.09.049

Gilchuk, Iuliia ; Gilchuk, Pavlo ; Sapparapu, Gopal ; Lampley, Rebecca ; Singh, Vidisha ; Kose, Nurgun ; Blum, David L. ; Hughes, Laura J. ; Satheshkumar, Panayampalli S. ; Townsend, Michael B. ; Kondas, Ashley V. ; Reed, Zachary ; Weiner, Zachary ; Olson, Victoria A. ; Hammarlund, Erika ; Raue, Hans Peter ; Slifka, Mark K. ; Slaughter, James C. ; Graham, Barney S. ; Edwards, Kathryn M. ; Eisenberg, Roselyn J. ; Cohen, Gary H. ; Joyce, Sebastian ; Crowe, James E. / Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections. In: Cell. 2016 ; Vol. 167, No. 3. pp. 684-694.e9.

@article{f9ffb1978c6946a5904914572c341b90,

title = "Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections",

abstract = "Monkeypox (MPXV) and cowpox (CPXV) are emerging agents that cause severe human infections on an intermittent basis, and variola virus (VARV) has potential for use as an agent of bioterror. Vaccinia immune globulin (VIG) has been used therapeutically to treat severe orthopoxvirus infections but is in short supply. We generated a large panel of orthopoxvirus-specific human monoclonal antibodies (Abs) from immune subjects to investigate the molecular basis of broadly neutralizing antibody responses for diverse orthopoxviruses. Detailed analysis revealed the principal neutralizing antibody specificities that are cross-reactive for VACV, CPXV, MPXV, and VARV and that are determinants of protection in murine challenge models. Optimal protection following respiratory or systemic infection required a mixture of Abs that targeted several membrane proteins, including proteins on enveloped and mature virion forms of virus. This work reveals orthopoxvirus targets for human Abs that mediate cross-protective immunity and identifies new candidate Ab therapeutic mixtures to replace VIG.",

keywords = "antigen specificity, cross-neutralization, human monoclonal antibodies, poxvirus infections, protective immunity, smallpox vaccine",

author = "Iuliia Gilchuk and Pavlo Gilchuk and Gopal Sapparapu and Rebecca Lampley and Vidisha Singh and Nurgun Kose and Blum, {David L.} and Hughes, {Laura J.} and Satheshkumar, {Panayampalli S.} and Townsend, {Michael B.} and Kondas, {Ashley V.} and Zachary Reed and Zachary Weiner and Olson, {Victoria A.} and Erika Hammarlund and Raue, {Hans Peter} and Slifka, {Mark K.} and Slaughter, {James C.} and Graham, {Barney S.} and Edwards, {Kathryn M.} and Eisenberg, {Roselyn J.} and Cohen, {Gary H.} and Sebastian Joyce and Crowe, {James E.}",

year = "2016",

month = oct,

day = "20",

doi = "10.1016/j.cell.2016.09.049",

language = "English (US)",

volume = "167",

pages = "684--694.e9",

journal = "Cell",

issn = "0092-8674",

publisher = "Cell Press",

number = "3",

}

TY - JOUR

T1 - Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections

AU - Gilchuk, Iuliia

AU - Gilchuk, Pavlo

AU - Sapparapu, Gopal

AU - Lampley, Rebecca

AU - Singh, Vidisha

AU - Kose, Nurgun

AU - Blum, David L.

AU - Hughes, Laura J.

AU - Satheshkumar, Panayampalli S.

AU - Townsend, Michael B.

AU - Kondas, Ashley V.

AU - Reed, Zachary

AU - Weiner, Zachary

AU - Olson, Victoria A.

AU - Hammarlund, Erika

AU - Raue, Hans Peter

AU - Slifka, Mark K.

AU - Slaughter, James C.

AU - Graham, Barney S.

AU - Edwards, Kathryn M.

AU - Eisenberg, Roselyn J.

AU - Cohen, Gary H.

AU - Joyce, Sebastian

AU - Crowe, James E.

PY - 2016/10/20

Y1 - 2016/10/20

N2 - Monkeypox (MPXV) and cowpox (CPXV) are emerging agents that cause severe human infections on an intermittent basis, and variola virus (VARV) has potential for use as an agent of bioterror. Vaccinia immune globulin (VIG) has been used therapeutically to treat severe orthopoxvirus infections but is in short supply. We generated a large panel of orthopoxvirus-specific human monoclonal antibodies (Abs) from immune subjects to investigate the molecular basis of broadly neutralizing antibody responses for diverse orthopoxviruses. Detailed analysis revealed the principal neutralizing antibody specificities that are cross-reactive for VACV, CPXV, MPXV, and VARV and that are determinants of protection in murine challenge models. Optimal protection following respiratory or systemic infection required a mixture of Abs that targeted several membrane proteins, including proteins on enveloped and mature virion forms of virus. This work reveals orthopoxvirus targets for human Abs that mediate cross-protective immunity and identifies new candidate Ab therapeutic mixtures to replace VIG.

AB - Monkeypox (MPXV) and cowpox (CPXV) are emerging agents that cause severe human infections on an intermittent basis, and variola virus (VARV) has potential for use as an agent of bioterror. Vaccinia immune globulin (VIG) has been used therapeutically to treat severe orthopoxvirus infections but is in short supply. We generated a large panel of orthopoxvirus-specific human monoclonal antibodies (Abs) from immune subjects to investigate the molecular basis of broadly neutralizing antibody responses for diverse orthopoxviruses. Detailed analysis revealed the principal neutralizing antibody specificities that are cross-reactive for VACV, CPXV, MPXV, and VARV and that are determinants of protection in murine challenge models. Optimal protection following respiratory or systemic infection required a mixture of Abs that targeted several membrane proteins, including proteins on enveloped and mature virion forms of virus. This work reveals orthopoxvirus targets for human Abs that mediate cross-protective immunity and identifies new candidate Ab therapeutic mixtures to replace VIG.

KW - antigen specificity

KW - cross-neutralization

KW - human monoclonal antibodies

KW - poxvirus infections

KW - protective immunity

KW - smallpox vaccine

UR - http://www.scopus.com/inward/record.url?scp=84992677658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992677658&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2016.09.049

DO - 10.1016/j.cell.2016.09.049

M3 - Article

C2 - 27768891

AN - SCOPUS:84992677658

VL - 167

SP - 684-694.e9

JO - Cell

JF - Cell

SN - 0092-8674

IS - 3

ER -